Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 420814 dose-finding study in Parkinson's disease with motor fluctuations and dyskinesias
2005-005146-39Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of preladenant in Parkinson's disease (PD) (5 arms), sponsored by Merck & Co. Primary endpoint: Primary efficacy endpoint. Started Dec 2006; status: completed.
02
Drugs
preladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2005-005146-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005146-39.